Treating cancer with a combination of a PD-1 antagonist and dinaciclib
US9827309B2 · kind B2 · utility
5Cited by
5References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 15, 2014 |
| Grant date | Nov 28, 2017 |
| Priority date | — |
| Expiry date | Aug 15, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2818
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.